NCT05743426
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 5 versions: 2 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Enrollment increased: 180 → 450 participants
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 2023 to Mar 17, 2023
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Disease-free survival
Timeframe: Up to 10 years
Secondary (5)
Local Control
Adverse Events
Quality of life PRO-CTCAE
Quality of life EQ-5D-5L
Quality of life Toronto Extremity Salvage Score (TESS)
Arms and interventions
Single Arm
Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
Other: Survey, Toxicity Assessments
Sites
1 site in 1 country
- University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, North Carolina, United States